As interest rates remain close to their historic lows, income investors continue to starve for any firm that has a growing dividend. Fortunately, the market always offers something for investors who are trying to build a safe dividend portfolio.
Read on to learn about 10 high quality, high yield blue chips trading close to 52-week lows and more importantly, why it is now a great time to add....more>>>
Schlumberger (NYSE:SLB), the world’s leading oilfield services company, has held up well in the downturn. Its revenues and profits have been declining, and, based on what we’ve heard recently from the company’s management, will likely continue heading lower. But unlike almost all of its peers, Schlumberger has reported quarterly profits and generated enough cash flows to fully....more>>>
You wouldn’t know it from the headlines about obesity, but Americans spend a lot of time and money on fitness — and that spending is rising every year. The aging of America, which eventually could be a drag on the fitness segment as the Baby Boom population gets extremely old, is still a net positive: doctors increasingly insist that seniors stay active, driving demand for athletic shoes....more>>>
India’s finance minister isn’t worried about jobs being lost in the country’s manufacturing sector despite warnings that industrial robots will dramatically reduce the need for factory workers in coming decades.
“I still have faith in human ingenuity, that even when jobs are lost in certain sectors … more jobs will be created because of that increased economic activity....more>>>
Since coming to the public markets in early 2013, Stemline Therapeutics (NASDAQ:STML) shareholders have experienced one heck of a ride.
The share price reached $47 on positive news for its leading drug candidate SL-401, with Roth Capital setting a $50 price target, Jefferies a $60 price target, Aegis a whopping $70 price target. Reasons for enthusiasm included....more>>>